<DOC>
	<DOCNO>NCT02521701</DOCNO>
	<brief_summary>This Phase I study investigate safety two dose level NFL-101 smoker .</brief_summary>
	<brief_title>Safety Efficacity NFL101 Tobacco Therapy</brief_title>
	<detailed_description>Tobacco addiction one big public health threat world ever face , kill nearly six million people year . There 1 billion smoker world , half eventually die tobacco-related disease . Nicotine replacement treatment first pharmacological treatment approve use smoke cessation therapy include nicotine gum , transdermal patch , tablet , nasal spray , inhalation system . More recently , buproprion varenicline approve show limit side effect . The development safe efficient alternative indication call . Tobacco cessation case observe concomitantly administration desensitization treatment tobacco allergy . Based observation , NFL Biosciences develop drug candidate tobacco cessation . This new drug ( NFL 101 ) assess preclinical study . Notably , regulatory genotoxicity ( Institut Pasteur de Lille ) toxicity study rat ( Ricerca , Wil Research , Lyon ) show toxicity . The NFL 101 composition low dos inject lead propose mechanism action base immune response . Immunogenicity study conduct European Georges Pompidou Hospital ( HEGP ) peripheral blood mononuclear cell rodent support hypothesis . Therefore , objective Phase I study investigate safety two dose level NFL-101 smoker .</detailed_description>
	<criteria>Male female subject ≥ 18 ≤ 70 year old ECOG/OMS performance status 01 Subjects currently smoke least 11 cigarette per day dependency level ≥ 5 accord Fagerstöm score Subjects willing quit smoking Good general health ( i.e . uncontrolled medical condition ) Good mental health ( i.e . alcohol drug abuse past year , psychiatric history adequately treat depression accept ) . For woman childbearing age : adequate contraception least 28 day second injection French speaking Patients must affiliate social security system Informed consent agreement signature Pregnancy breastfeed Concomitant participation another clinical trial Concomitant active infectious disease Concomitant desensitization therapy History asthma immune disorder History allergy include nicotine component study product Uncontrolled diabetes Use corticosteroid , systemic steroid , antihistamine immunosuppressive agent within 30 day prior study start Prior exposure nicotine vaccine vaccine within 30 day study product administration Use therapy smoking cessation within 90 day ( include use electronic cigarette alternative method hypnosis acupuncture ) Legal incapacity physical , psychological mental status interfere subject 's ability sign inform consent terminate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>